Gallium citrate Withdrawn Phase 2 Trials for Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) Diagnostic

IndicationsStatusPurposePhase
WithdrawnDiagnostic2
clinicaltrials.gov IdentifierTitleDrugs
NCT02776891A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma